Perbak Capital Partners’s Amgen AMGN Stock Holding History

Perbak Capital Partners’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,050	Closed	-$953K	–	32
2024 Q2	$953K	Buy	+3,050	New	+$896K	0.28%	53

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Perbak Capital Partners's AMGN Position: Q3 2024 in Review

Perbak Capital Partners sold out of Amgen (AMGN) in Q3 2024, closing a stake of 3,050 shares — an estimated $953K sold.

Perbak Capital Partners first reported a position in AMGN in Q2 2024 and held it in 1 quarter. The position peaked at $953K in Q2 2024. 2,824 funds tracked by Wall St. Rank hold AMGN as of Q3 2024.

Perbak Capital Partners reported no remaining Amgen position as of Q3 2024 after selling out during the quarter.
Perbak Capital Partners sold 3,050 Amgen shares in Q3 2024, an estimated $953K.
Perbak Capital Partners first reported a position in Amgen in Q2 2024 and held it in 1 quarter.
Perbak Capital Partners's Amgen position peaked at $953K in Q2 2024.
2,824 funds tracked by Wall St. Rank held Amgen as of Q3 2024.

Based on Perbak Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.